Imfinzi (durvalumab) / AstraZeneca  >>  Phase 3
Welcome,         Profile    Billing    Logout  

95 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imfinzi (durvalumab) / AstraZeneca
ACTRN12620001199909: DREAM3R: A phase 3 trial of durvalumab with chemotherapy as first line treatment in mesothelioma

Recruiting
3
480
 
University of Sydney, AstraZeneca Pty Ltd
Pleural Mesothelioma (PM)
 
 
jRCTs031210393: JCOG2002: A randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer

Recruiting
3
330
Japan
carboplatin - Generic mfg., etoposide oral - Generic mfg., cisplatin - Generic mfg., Tecentriq (atezolizumab) - Roche, Imfinzi (durvalumab) - AstraZeneca
Dokkyo Medical University Hospital, National Cancer Center Japan
Extensive stage small cell lung cancer
 
 
PaciFIC, NCT02125461 / 2014-000336-42: A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Checkmark Data from PACIFIC trial for stage III unresectable NSCLC at ASCO 2021
Jun 2021 - Jun 2021: Data from PACIFIC trial for stage III unresectable NSCLC at ASCO 2021
Checkmark Presentation of data from PACIFIC trial in stage 3 unresectable NSCLC at ASCO 2021
Jun 2021 - Jun 2021: Presentation of data from PACIFIC trial in stage 3 unresectable NSCLC at ASCO 2021
Checkmark Data from PACIFIC trial in stage 3 unresectable NSCLC at ESMO 2020
More
Completed
3
713
Europe, Canada, Japan, US, RoW
MEDI4736, PLACEBO
AstraZeneca
Non-Small Cell Lung Cancer
02/17
08/23
CAURAL, NCT02454933: Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Checkmark CAURAL trial of durvalumab in combination with osimertinib second-line T790M+ NSCLC
Feb 2019 - Feb 2019: CAURAL trial of durvalumab in combination with osimertinib second-line T790M+ NSCLC
Checkmark Of P3 CAURAL trial of Tagrisso + durvalumab in second-line advanced EGFRm T790M NSCLC due to safety/efficacy reason
Apr 2016 - Apr 2016: Of P3 CAURAL trial of Tagrisso + durvalumab in second-line advanced EGFRm T790M NSCLC due to safety/efficacy reason
Completed
3
29
Canada, RoW
AZD9291, MEDI4736
AstraZeneca
Locally Advanced or Metastatic EGFR T790M+ NSCLC
08/17
06/23
ARCTIC, NCT02352948 / 2014-000338-46: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Checkmark ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
Apr 2018 - Apr 2018: ARCTIC trial of durvalumab in combination with tremelimumab in PD-L1 negative NSCLC
Checkmark Completion of enrollment in P3 ARCTIC in durvalumab + tremelimumab for 3L NSCLC
Aug 2016 - Aug 2016: Completion of enrollment in P3 ARCTIC in durvalumab + tremelimumab for 3L NSCLC
Checkmark ARCTIC monotherapy trial for stage IIIB-IV NSCLC
More
Completed
3
597
Europe, Canada, Japan, US, RoW
MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4)
AstraZeneca
Non - Small Cell Lung Cancer NSCLC
02/18
08/23
MYSTIC, NCT02453282 / 2015-001279-39: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Checkmark From MYSTIC trial in 1L mNSCLC
Apr 2020 - Apr 2020: From MYSTIC trial in 1L mNSCLC
Checkmark Results for metastatic NSCLC [MYSTIC]
Dec 2018 - Dec 2018: Results for metastatic NSCLC [MYSTIC]
Checkmark OS data from MYSTIC trial in 1L NSCLC
More
Active, not recruiting
3
1118
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
10/18
12/24
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
2018-002294-22: Study of Durvalumab as consolidation therapy in lung cancer (PACIFIC-5 Study) Badanie oceniające durwalumab w terapii konsolidacyjnej u pacjentów z rakiem płuca (Badanie PACIFIC-5)

Not yet recruiting
3
400
Europe
durvalumab, MEDI4736, Concentrate for solution for infusion
AstraZeneca AB, AstraZeneca AB
Locally Advanced unresectable, non small cell lung cancer who have not progressed following definitive, platinum-based chemoradiation therapy Miejscowo zaawansowany, nieoperacyjny niedrobnokomórkowy rak płuca bez progresji po definitywnej, opartej na pochodnych platyny, chemioradioterapii, Specific type of lung cancer called "non small cell lung cancer" Określony typ raka płuca nazywany „niedrobnokomórkowym rakiem płuca”, Diseases [C] - Cancer [C04]
 
 
2018-001811-59: This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Not yet recruiting
3
1050
Europe
durvalumab, MEDI4736, Concentrate for solution for infusion, Remicade 100mg powder for concentrate for solution for infusion, Celicept 250mg Capsules, Micofenolato Mofetile, Mycophenolate mofetil Sandoz 250 mg, Inflectra 100 mg powder for concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder, Muscle Invasive Bladder Cancer (T2-T4a) in stage II and IIIA without lymph node involvement, Diseases [C] - Cancer [C04]
 
 
2018-001155-13: Chemotherapy with or without Durvalumab in early-stage triple-negative breast cancer Chemotherapie mit oder ohne Durvalumab bei triple-negativem Brustkrebs im Frühstadium

Completed
3
1528
Europe
MEDI4736, Concentrate for solution for infusion
GBG Forschungs GmbH, AstraZeneca UK Limited
Early-staged triple-negative breast cancer Früher triple-negativer Brustkrebs, Triple-negative breast cancer (TNBC) Triple-negativer Brustkrebs, Diseases [C] - Cancer [C04]
 
 
2018-004105-85: A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence

Not yet recruiting
3
888
Europe
Durvalumab, Bevacizumab, MEDI4736, RO487-6646/F02, Concentrate and solvent for solution for infusion, Concentrate for solution for infusion, AVASTIN
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Histologically or cytologically (or radiologically for patients undergoing curative ablation) confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or Ablation), Early stage HCC patients, Diseases [C] - Cancer [C04]
 
 
DANUBE , NCT02516241 / 2015-001633-24: Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Checkmark From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Sep 2020 - Sep 2020: From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Checkmark From DANUBE trial in combination with durvalumab vs chemo in Stage IV urothelial cancer
Sep 2020 - Sep 2020: From DANUBE trial in combination with durvalumab vs chemo in Stage IV urothelial cancer
Hourglass Mar 2020 - Jun 2020 : Regulatory submission in EU (based on DANUBE trial) for 1L bladder cancer in combination with tremelimumab
More
Active, not recruiting
3
1126
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine
AstraZeneca
Urothelial Cancer
01/20
12/24
CASPIAN, NCT03043872 / 2016-001203-23: Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer

Checkmark From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Sep 2021 - Sep 2021: From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Checkmark From CASPIAN trial in 1L SCLC at ESMO 2020
Sep 2020 - Sep 2020: From CASPIAN trial in 1L SCLC at ESMO 2020
Checkmark From CASPIAN trial in combination with tremelimumab for 1L extensive-stage SCLC at ASCO 2020
More
Active, not recruiting
3
987
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
01/20
12/24
ACTRN12615000323527: A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

Active, not recruiting
3
110
 
NHMRC Clinical Trials Centre, Canadian Cancer Trials Group
Lung cancer
 
 
NEPTUNE, NCT02542293 / 2015-002197-21: Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC)

Checkmark From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Aug 2019 - Aug 2019: From NEPTUNE trial in combination with tremelimumab in 1L NSCLC
Active, not recruiting
3
953
Europe, Japan, US, RoW
Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
09/20
12/24
POSEIDON, NCT03164616 / 2017-000920-81: Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer ().

Checkmark Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2022
Checkmark Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Aug 2022 - Aug 2022: Post-hoc exploratory analyses from POSEIDON trial in combination with tremelimumab for 1L NSCLC at IASLC-WCLC 2022
Checkmark Full data presentation from POSEIDON trial in combination with tremelimumab for stage IV 1L NSCLC at ESMO 2021
More
Active, not recruiting
3
1186
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin
AstraZeneca
Non Small Cell Lung Cancer NSCLC
03/21
12/26
2020-001001-22: Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With locally advanced, unresctable ESCC

Not yet recruiting
3
600
Europe
Durvalumab, Cisplatin, capecitabine, 5-fluorouracil, MEDI4736, Concentrate for solution for infusion, Film-coated tablet, Solution for infusion, Cisplatin NeoCorp® 1 mg/mL - concentrate for solution for infusion, Capecitabine (Capecitabin cell pharm® 150 mg and 500 mg film-coated tablets), 5-FU medac 50 mg/ml, solution for injection, Capecitabine Accord 150 mg and 500 mg film coated tablets, Cisplatin Teva® 1 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Benda-5 FU 50 mg/ml, solution for injection
AstraZeneca AB, AstraZeneca AB
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma, Specific type of Esophageal cancer called "Esophageal Squamous Cell Carcinoma" (ESCC) that cannot be removed by surgery, Diseases [C] - Cancer [C04]
 
 
2021-000615-23: Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with metastatic cancer in response after 6 months of standard IO

Not yet recruiting
3
646
Europe
pembrolizumab, durvalumab, atezolizumab, avelumab, bevacizumab, pemetrexed, cabozantinib, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Film-coated tablet, OPDIVO, KEYTRUDA, IMFINZI, Tecentriq, Bavencio
UNICANCER, PHRC-K 2020, Fondation BMS
Oncologic metastatic tumour (lung cancer (K), renal cell K (except IMDC favorable-risk treated TKI / immunotherapy [IO] combination), head and neck K, bladder K, triple negative breast K, Merkel K and melanoma, or hepatocellular carcinoma) in PR or CR (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI)., -, Diseases [C] - Cancer [C04]
 
 
TOPAZ-1, NCT03875235 / 2018-004688-30: Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer

Checkmark Data from TOPAZ-1 trial for biliary tract cancer at ESMO World GI 2022
Jul 2022 - Jul 2022: Data from TOPAZ-1 trial for biliary tract cancer at ESMO World GI 2022
Checkmark Data from TOPAZ-1 trial for biliary tract cancer at ASCO GI 2022
Jan 2022 - Jan 2022: Data from TOPAZ-1 trial for biliary tract cancer at ASCO GI 2022
Checkmark From P3 TOPAZ-1 trial for 1L BTC at ASCO-GI 2022
More
Active, not recruiting
3
810
Europe, Japan, US, RoW
Durvalumab, Placebo
AstraZeneca
Biliary Tract Neoplasms
08/21
03/25
HIMALAYA, NCT03298451 / 2016-005126-11: Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Hourglass Jan 2023 - Dec 2023 : Regulatory decision in EU in combination with Imfinzi for 1L HCC (based on HIMALAYA trial)
Checkmark From HIMALAYA trial in combination with tremelimumab for 1L unresectable HCC at ASCO-GI 2023
Jan 2023 - Jan 2023: From HIMALAYA trial in combination with tremelimumab for 1L unresectable HCC at ASCO-GI 2023
Checkmark From HIMALAYA trial in combination with tremelimumab for 1L unresectable HCC at ESMO World GI 2022
Jul 2022 - Jul 2022: From HIMALAYA trial in combination with tremelimumab for 1L unresectable HCC at ESMO World GI 2022
More
Active, not recruiting
3
1324
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2)
AstraZeneca
Hepatocellular Carcinoma
08/21
08/24
2021-001648-91: Does radiotherapy given in addition to immunotherapy and chemotherapy prolong survival in patients with extended stage small-cell lung cancer?

Not yet recruiting
3
294
Europe
Imfinzi, Concentrate for solution for infusion, Imfinzi
Norwegian University of Science and Technology, The national programme for clinical therapy research in the specialist health service, Astra Zeneca
Extensive stage small-cell lung cancer, Small-cell lung cancer which has metastasized outside the chest., Diseases [C] - Cancer [C04]
 
 
2021-000336-55: A clinical trial to compare the effectiveness of savolitinib plus durvalumab relative to durvalumab and sunitinib alone for the treatment of renal cell cancer

Not yet recruiting
3
200
RoW, Europe
Savolitinib, Durvalumab, AZD6094, HMPL-504, MEDI4736, Tablet, Concentrate for solution for infusion, Capsule, hard, Sutent 25 mg hard capsules, Sutent 12.5 mg hard capsules
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma, unresectable and locally advanced or metastatic renal cell cancer, Diseases [C] - Cancer [C04]
 
 
2021-000518-40: RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, The MMRD-GREEN trial

Not yet recruiting
3
316
Europe
Durvalumab, Solution for infusion, IMFINZI
Leiden University Medical Center, Dutch Cancer Society / KWF and Astra Zeneca
Endometrial Cancer, stage II plus LVSI and stage III MMRd endometrial cancer baarmoederkanker, Diseases [C] - Cancer [C04]
 
 
CALLA, NCT03830866 / 2018-002872-42: Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer

Checkmark Presentation of data from CALLA trial for advanced cervical cancer at IGCS 2022
Sep 2022 - Sep 2022: Presentation of data from CALLA trial for advanced cervical cancer at IGCS 2022
Checkmark From CALLA trial for advanced cervical cancer
Mar 2022 - Mar 2022: From CALLA trial for advanced cervical cancer
Completed
3
770
Europe, Japan, US, RoW
Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
AstraZeneca
Locally Advanced Cervical Cancer
01/22
07/23
2021-005135-23: A study of MK7684A in Combination with radiation and chemotherapy versus radiation and chemotherapy followed by Durvalumab for patients with Stage III lung cancer that cannot be surgically treated Estudio de MK-7684A en combinación con quimiorradioterapia en comparación con quimiorradioterapia seguida de durvalumab en participantes con CPNM en estadio III que no puede ser tratado quirúrgicamente.

Not yet recruiting
3
784
Europe
MK-7684A, Durvalumab, MK-7684A, Solution for infusion, Concentrate for solution for infusion, Imfinxi
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
Unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) Cáncer de pulmón no microcítico (CPNM) irresecable, localmente avanzado y en estadio III, Non-small cell lung cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
2020-005452-38: Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse Cisplatin

Not yet recruiting
3
830
Europe
Durvalumab, Tremelimumab, Enfortumab vedotin, MEDI4736, EV, Concentrate for solution for infusion, Powder for solution for infusion, IMFINZI, Padcev
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Documented muscle-invasive urothelial carcinoma (UC) of the bladder incisplatin ineligible patients or Who Refuse Cisplatin, Cancer in thick muscle in the bladder wall, Diseases [C] - Cancer [C04]
 
 
PEARL, NCT03003962 / 2018-001375-21: Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer

Checkmark Data from PEARL trial for Stage IV (metastatic) NSCLC
Dec 2022 - Dec 2022: Data from PEARL trial for Stage IV (metastatic) NSCLC
Checkmark From PEARL trial for 1L NSCLC
Oct 2021 - Oct 2021: From PEARL trial for 1L NSCLC
Active, not recruiting
3
669
Europe, US, RoW
Durvalumab (MEDI4736), Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin
AstraZeneca
Non Small Cell Lung Carcinoma NSCLC
10/22
06/26
AEGEAN, NCT03800134 / 2018-002997-29: A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Event free survival data from AEGEAN trial for stage I and III resected NSCLC
Jan 2023 - Dec 2023: Regulatory submission for locally advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU for advanced stage 3 NSCLC (based on AEGEAN trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan for advanced stage 3 NSCLC (based on AEGEAN trial)
Jan 2023 - Dec 2023: From AEGEAN trial for stage II and III resected NSCLC
More
Active, not recruiting
3
826
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Placebo, Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Gemcitabine, Surgery
AstraZeneca
Non-Small Cell Lung Cancer
11/22
09/28
Oriental, NCT04449861: Durvalumab Plus Chemotherapy in ES-SCLC

Completed
3
166
RoW
Durvalumab plus chemotherapy
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
03/23
03/23
MERMAID-2, NCT04642469 / 2020-000612-30: Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Calendar Jan 2024 - Dec 2024: Data from MERMAID-2 trial for NSCLC
Completed
3
30
Europe, Canada, Japan, US, RoW
Durvalumab, Medi4736, Placebo
AstraZeneca
Carcinoma, Non- Small Cell Lung
05/23
01/24
CANTABRICO, NCT04712903: Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer

Completed
3
101
Europe
Durvalumab, Cisplatin, Etoposide, Carboplatin
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
06/23
06/23
MERMAID-1, NCT04385368 / 2020-000556-35: Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

Calendar Jan 2024 - Dec 2024: Data from MERMAID-1 trial for stage II-III NSCLC
Calendar Jan 2023 - Dec 2024: Regulatory submission for adjuvant NSCLC (based on MERMAID-1 trial)
Completed
3
89
Europe, Canada, Japan, US, RoW
Durvalumab + SoC chemotherapy, MEDI4736, Placebo + SoC chemotherapy, Placebo
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/23
08/23
PACIFIC2, NCT03519971 / 2017-004397-34: Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

Jul 2023 - Dec 2023: Acceptance of regulatory submission for CRT+ NSCLC (based on PACIFIC-2 trial)
Jul 2023 - Dec 2023: Data from PACIFIC-2 trial for advanced NSCLC
Hourglass Jan 2021 - Dec 2021 : Regulatory submission for advanced stage 3 NSCLC (based on PACIFIC-2 trial)
Active, not recruiting
3
328
Europe, Japan, RoW
Durvalumab, MEDI4736, Placebo, Cisplatin/ Etoposide, Carboplatin/ Paclitaxel, Pemetrexed/ Cisplatin, Pemetrexed/ Carboplatin, Radiation
AstraZeneca
Non-Small Cell Lung Cancer
09/23
03/25
EMERALD-1, NCT03778957 / 2018-002134-20: A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

Hourglass Jul 2023 - Dec 2023 : Data from EMERALD-1 trial for HCC
Active, not recruiting
3
724
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Bevacizumab, AVASTIN, Placebo, Transarterial Chemoembolization (TACE)
AstraZeneca
Hepatocellular Carcinoma
09/23
08/26
DUO-O, NCT03737643 / 2017-004632-11: Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in US in combination with Imfinzi for 1L ovarian cancer (based on DUO-O trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Lynparza for 1L ovarian cancer (based on DUO-O trial)
Jan 2023 - Jun 2023: Data from DuO-O trial in combination with Imfinzi for advanced ovarian cancer
Active, not recruiting
3
1407
Europe, Canada, Japan, US, RoW
Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
AstraZeneca, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Inc. (GOG Foundation), Myriad Genetic Laboratories, Inc.
Advanced Ovarian Cancer
09/23
05/28
DUO-E, NCT04269200 / 2019-004112-60: Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi for endometrial cancer (based on DuO-E trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Lynparza for endometrial cancer (based on DuO-E trial)
Jan 2022 - Dec 2023: From STRONG trial in combinaton with tremelimumab advanced solid malignancies
Jul 2023 - Dec 2023: Data from DUO-E trial in combination with Imfinzi for 1L endometrial cancer
Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in Japan in combination with Lynparza (based on DuO-E trial) for 1L endometrial cancer
More
Active, not recruiting
3
805
Europe, Canada, Japan, US, RoW
olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel
AstraZeneca, The Gynecologic Oncology Group (GOG) Foundation Inc, The European Network for Gynaecological Oncological Trial groups (ENGOT)
Endometrial Neoplasms
07/24
08/27
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
NILE, NCT03682068 / 2018-001883-48: Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

Hourglass Jul 2023 - Dec 2023 : Data from NILE trial in combination with tremelimumab for 1L bladder cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission (based on NILE trial) in combination with Imfinzi for urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission based on NILE trial in EU in combination with tremelimumab for 1L urothelial cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU in combination with Imfinzi for 1L urothelial cancer (based on NILE trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan in combination with tremelimumab for 1L urothelial cancer based on NILE trial
More
Active, not recruiting
3
1244
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine
AstraZeneca
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
08/24
06/25
NCT04585490: Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Recruiting
3
48
US
Durvalumab, Imfinzi, MEDI-4736, MEDI4736, Carboplatin, Carboplat, Carbosol, Carboplatino, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum, Pemetrexed, Alimta, MTA, LY231514, L-glutamic acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), Paclitaxel, Praxel, Cisplatin, platinum diamminodichloride, Abiplatin, Cismaplat, cis-platinum, Platinex, platinum, diaminedichloro-, cis- (8CI), AVENIO ctDNA Surveillance Kit, Tremelimumab, Imjudo, Tremelimumab-actl, Ticilimumab, CP-675, CP-675,206
Maximilian Diehn, AstraZeneca
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
04/26
04/28
LUMINANCE, NCT04774380 / 2020-005537-32: Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

Active, not recruiting
3
152
Europe, Canada, RoW
Durvalumab, Cisplatin, Carboplatin, Etoposide
AstraZeneca
Extensive-stage Small Cell Lung Cancer
06/23
12/24
DREAM3R, NCT04181411: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Not yet recruiting
3
480
NA
Durvalumab, Imfinzi, MEDI4736, Cisplatin, Cisplatin injection, Pemetrexed, Alimta, Carboplatin, Carboplatin injection
University of Sydney, Australasian Lung Cancer Trials Group, PrECOG, LLC., AstraZeneca
Mesothelioma Malignant Advanced
06/24
06/24
DeLLphi-305, NCT06211036: Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

Recruiting
3
550
Europe, Japan, US, RoW
Tarlatamab, AMG 757, Durvalumab
Amgen
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
09/27
09/28
PACIFIC-5, NCT03706690: A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

Jan 2023 - Dec 2023: Acceptance of regulatory submission in China for locally advanced NSCLC (based on PACIFIC-5 trial)
Jan 2023 - Jun 2023: Data from PACIFIC-5 trial for advanced NSCLC
Active, not recruiting
3
407
Europe, RoW
Durvalumab, MEDI4736, Placebo
AstraZeneca
Carcinoma, Non-Small-Cell Lung
06/24
03/27
DESTINY-BTC01, NCT06467357: Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Not yet recruiting
3
620
Europe, Canada, Japan, RoW
Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, DS-8201a; T-DXd, Rilvegostomig, Agilent HercepTest™ mAb pharmDx, Ventana PD-L1 SP263 assay
AstraZeneca, Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo
Biliary Tract Cancer
04/28
03/29
NCT06282575: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Recruiting
3
286
US
Zanidatamab, ZW25, JZP598, Cisplatin, Gemcitabine, Pembrolizumab, Durvalumab
Jazz Pharmaceuticals
Biliary Tract Cancer, HER2 Gene Mutation
07/28
11/29
RAMPART, NCT03288532 / 2017-002329-39: Renal Adjuvant MultiPle Arm Randomised Trial

Hourglass Oct 2023 - Dec 2023 : From RAMPART trial with or without in combination with tremelimumab
Recruiting
3
1750
Europe
Durvalumab, Tremelimumab
University College, London, AstraZeneca, Kidney Cancer UK, Cancer Research UK
Renal Cell Carcinoma
07/24
12/34
EMERALD-2, NCT03847428: Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in China for HCC based on EMERALD-2 trial
Jan 2023 - Jun 2023: Data from EMERALD-2 trial for HCC
Active, not recruiting
3
908
Europe, Canada, Japan, US, RoW
Durvalumab, IMFINZI, Bevacizumab, AVASTIN, Placebo
AstraZeneca
Hepatocellular Carcinoma
05/26
05/27
ADRIATIC, NCT03703297 / 2018-000867-10: Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Jan 2022 - Dec 2023: Regulatory submission in China (based on ADRIATIC trial) in combination with Imfinzi for SCLC
Jul 2023 - Dec 2023: Acceptance of regulatory submission in combination with tremelimumab for SCLC cancer (based on ADRIATIC trial)
Jul 2023 - Dec 2023: Acceptance of regulatory submission in combination with Imfinzi for SCLC (based on ADRIATIC trial)
Jan 2023 - Jun 2023: Data from ADRIATIC trial in combination with tremelimumab for stage I-III SCLC
Active, not recruiting
3
730
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Tremelimumab, Placebo
AstraZeneca
Small Cell Lung Cancer
09/24
09/24
ADOPT-lung, NCT06284317: A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Not yet recruiting
3
290
NA
Adjuvant durvalumab
ETOP IBCSG Partners Foundation, AstraZeneca AG Switzerland
Non Small Cell Lung Cancer
10/29
03/30
SKYSCRAPER-03, NCT04513925 / 2019-004773-29: A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Calendar Jan 2025 - Dec 2025: From SKYSCRAPER-03 trial in combination with Tecentriq for unresectable stage 3 NSCLC
Active, not recruiting
3
829
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq; RO5541267, Tiragolumab, MTIG7192A; RO7092284, Durvalumab
Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
10/24
12/27
TopDouble, NCT05924880: A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)

Active, not recruiting
3
116
RoW
durvalumab, IMFINZI
AstraZeneca
Biliary Tract Cancers
10/24
05/25
POTOMAC, NCT03528694 / 2017-002979-26: Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Calendar Jan 2024 - Dec 2024: Data from POTOMAC trial for NMIBC
Calendar Jan 2023 - Dec 2024: Acceptance of regulatory submission for NMIBC (based on POTOMAC trial)
Active, not recruiting
3
1018
Europe, Canada, Japan, RoW
Durvalumab (MEDI4736), Bacillus Calmette-Guerin (BCG)
AstraZeneca
Non-muscle-invasive Bladder Cancer
10/24
09/25
NCT01993810: Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Active, not recruiting
3
330
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed Disodium, Alimta, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, PBRT, Proton Radiation Therapy, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
12/24
10/25
MATTERHORN, NCT04592913 / 2019-001555-40: Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for neo-adjuvant/adjuvant gastric (based on MATTERHORN trial)
Calendar Jan 2024 - Dec 2024: Data from MATTERHORN trial for gastric and gastroesophageal Cancer
Hourglass Jul 2020 - Dec 2020 : From trial for MDS
Active, not recruiting
3
958
Europe, Canada, Japan, US, RoW
Durvalumab, FLOT chemotherapy
AstraZeneca
Gastrointestinal Neoplasms, Esophagogastric Junction
10/25
09/27
TREMENDOUS, NCT05557838: Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma

Recruiting
3
210
RoW
Durvalumab, MEDI4736, Tremelimumab
AstraZeneca
Hepatocellular Carcinoma
03/25
03/25
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
04/25
12/25
ADJUVANT BR.31, NCT02273375 / 2014-004946-83 / ACTRN12615000323527: Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Calendar Jan 2024 - Dec 2024: Data from ADJUVANT BR.31 trial for NSCLC
Checkmark For P3 stage IB-IIIA resected NSCLC trial
Feb 2015 - Feb 2015: For P3 stage IB-IIIA resected NSCLC trial
Checkmark ADJUVANT trial for NSCLC
Oct 2014 - Oct 2014: ADJUVANT trial for NSCLC
Active, not recruiting
3
1415
Europe, Canada, Japan, US, RoW
MEDI4736, Placebo
Canadian Cancer Trials Group, Intergroupe Francophone de Cancerologie Thoracique, Thoracic Oncology Group of Australasia (TOGA), National Health and Medical Research Council, Australia, National Cancer Institute (NCI), Naples, Central and Eastern European Oncology Group, Dutch Society of Physicians for Pulmonology and Tuberculosis, Korean Cancer Study Group, Fundación GECP, West Japan Oncology Group (WJOG), Chinese Thoracic Oncology Group
Non-Small Cell Lung Cancer
04/25
01/26
ROSY-D, NCT05303532 / 2021-003031-29: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

Enrolling by invitation
3
61
Europe, Canada, Japan, US, RoW
Durvalumab
AstraZeneca, AstraZeneca AB
Cancer
05/25
05/25
LATIFY, NCT05450692 / 2022-000493-26: A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Active, not recruiting
3
563
Europe, Canada, Japan, US, RoW
Ceralasertib, Durvalumab, Docetaxel
AstraZeneca, Parexel
Advanced or Metastatic Non-Small Cell Lung Cancer
05/25
08/25
SAMETA, NCT05043090: Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Recruiting
3
220
Europe, Canada, US, RoW
savolitinib, AZD6094, HMPL-504, volitinib, durvalumab, MEDI4736, sunitinib, Sutent, SU11248
AstraZeneca
Papillary Renal Cell Carcinoma
05/25
09/26
NIAGARA, NCT03732677: Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

Jul 2023 - Dec 2023: From NIAGARA trial for muscle-invasive bladder cancer
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in EU for MIBC (based on NIAGARA trial)
Hourglass Jan 2022 - Dec 2023 : Regulatory submission in Japan for MIBC (based on NIAGARA trial)
Active, not recruiting
3
1063
Europe, Canada, Japan, US, RoW
Durvalumab, Cisplatin, Gemcitabine
AstraZeneca
Muscle Invasive Bladder Cancer
06/25
06/26
SIERRA, NCT05883644: Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

Recruiting
3
110
Europe, Japan, US, RoW
Durvalumab, Tremelimumab
AstraZeneca
Advanced Hepatocellular Carcinoma
06/25
12/25
CheckMate 73L, NCT04026412 / 2019-001222-98: A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Calendar Jan 2025 - Dec 2025: Data from CheckMate73L trial in combination with Yervoy and Imfinzi for unresectable stage III NSCLC
Hourglass Jul 2018 - Dec 2018 : In 1L TMB-high NSCLC
Hourglass Jul 2018 - Dec 2018 : In 1L TMB-high NSCLC
Active, not recruiting
3
888
Europe, Canada, Japan, US, RoW
nivolumab, ipilimumab, durvalumab
Bristol-Myers Squibb
Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
VOLGA, NCT04960709: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with tremelimumab and Padcev for MIBC (based on VOLGA trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Padcev and Imfinzi for MIBC (based on VOLGA trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi and tremelimumab for MIBC (based on VOLGA trial)
Calendar Jan 2024 - Dec 2024: Data from VOLGA trial in combination with tremelimumab and Padcev for MIBC
Recruiting
3
830
Europe, Canada, Japan, US, RoW
Durvalumab, IMFINZI, MEDI4736, Tremelimumab, Enfortumab Vedotin, PADCEV, Radical Cystectomy
AstraZeneca
Muscle Invasive Bladder Cancer
07/25
09/28
PATAPSCO, NCT05943106: BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

Recruiting
3
100
US
Durvalumab, BCG
AstraZeneca, Parexel
Non-Muscle- Invasive Bladder Cancer
09/25
05/27
KUNLUN, NCT04550260: Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

Calendar Jan 2024 - Dec 2024: Data from KUNLUN trial for esophageal squamous cell carcinoma
Active, not recruiting
3
640
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine, Radiation
AstraZeneca
Esophageal Squamous Cell Carcinoma
11/25
11/26
EMERALD-3, NCT05301842 / 2021-003822-54: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with tremelimumab for HCC (based on EMERALD-3 trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi for HCC (based on EMERALD-3 trial)
Calendar Jan 2024 - Dec 2024: Data from EMERALD-3 trial in combination with tremelimumab for HCC
Recruiting
3
725
Europe, Canada, Japan, US, RoW
Tremelimumab, MEDI1123, Durvalumab, MEDI4736, Transarterial Chemoembolization (TACE), DEB-TACE and cTACE, Lenvatinib, Lenvima
AstraZeneca
Hepatocellular Carcinoma
12/25
02/27
NCT06031597: Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Not yet recruiting
3
105
NA
radiotherapy, Platinum-Based Drug, Cisplatin, Immunotherapy, Nivolumab, Atezolizumab, Durvalumab, Pembrolizumab, Tislelizumab, Sugemalimab, Sintilimab, Camrelizumab, Immunotherapeutic Agent
Zhejiang Cancer Hospital
Non-small Cell Lung Cancer Stage III
12/25
12/25
TRIPLEX, NCT05223647: Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer

Recruiting
3
302
Europe, RoW
Thoracic radiotherapy, Chemo-immunotherapy, carboplatin/etoposide/durvalumab
Norwegian University of Science and Technology, St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, Alesund Hospital, Helse Stavanger HF, Oslo University Hospital, Helse Nord-Trøndelag HF, Helse Fonna, Drammen sykehus, University Hospital, Akershus, Erasmus Medical Center, Sahlgrenska University Hospital, Sweden, Karolinska University Hospital, Gävle Hospital, Sykehuset Innlandet HF, North Estonia Medical Centre, Nordlandssykehuset HF, Landspitali University Hospital, Lund University Hospital, University Hospital, Linkoeping
Small-cell Lung Cancer
01/26
10/29
PACIFIC-4, NCT03833154 / 2018-002572-41: Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

Calendar Jan 2024 - Dec 2024: Acceptance of submission for NSCLC (based on PACIFIC-4 trial)
Calendar Jan 2024 - Dec 2024: Data from PACIFIC-4 trial for stage I/II NSCLC
Recruiting
3
690
Europe, Canada, Japan, US, RoW
Durvalumab, MEDI4736, Placebo, Osimertinib (single-arm, open-label)
AstraZeneca
Carcinoma, Non-Small-Cell Lung
03/26
04/28
TOURMALINE, NCT05771480: Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Recruiting
3
140
Europe, Japan, US, RoW
Durvalumab, Background Gemcitabine-based Chemotherapy Regimen, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin, Gemcitabine + cisplatin + S-1, Background Gemcitabine-based Chemotherapy Regimen., This regimen is not allowed for countries in the European Union., Gemcitabine + S-1, Gemcitabine + cisplatin + albumin-bound paclitaxel, Background gemcitabine-based chemotherapy Regimen
AstraZeneca
Biliary Tract Cancer
09/25
03/26
PACIFIC-9, NCT05221840 / 2021-004346-37: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for stage 3 unresectable NSCLC (based on PACIFIC-9 trial) in combination with oleclumab and monalizumab
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for stage 3 unresectable NSCLC (based on PACIFIC-9 trial) in combination with Imfinzi and monalizumab
Calendar Jan 2024 - Dec 2024: Data from PACIFIC-9 trial in combination with oleclumab and monalizumab for stage 3 unresectable NSCLC
Calendar Jan 2024 - Dec 2024: Data from PACIFIC-9 trial in combination with oleclumab and monalizumab for stage 3 unresectable NSCLC
Recruiting
3
999
Europe, Canada, Japan, US, RoW
Durvalumab, Oleclumab, Monalizumab, Placebo
AstraZeneca
Non-Small Cell Lung Cancer
05/26
05/30
NCT06058377: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Recruiting
3
3680
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Genetic Testing, Genetic Analysis, Genetic Examination, Genetic Test, Mammography, MG, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Localized Breast Carcinoma
05/26
05/26
NCT04637594: Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

Active, not recruiting
3
3
US
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma
07/26
09/30
KEYLYNK-012, NCT04380636 / 2019-003237-41: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/)

Calendar Jan 2026 - Dec 2026: Data from KEYLINK-012 trial in combination with Lynparza for stage III NSCLC
Active, not recruiting
3
870
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, LYNPARZA®, MK-7339, AZD2281, KU-0059436, Placebo for olaparib, Etoposide, VEPESID®, Carboplatin, PARAPLATIN®, Cisplatin, PLATINOL®, Paclitaxel, TAXOL®, Pemetrexed, ALIMTA®, Thoracic Radiotherapy, Durvalumab, IMFINZI®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
07/26
02/27
TROPION-Breast05, NCT06103864: A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Recruiting
3
625
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Durvalumab, MEDI4736, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin, Pembrolizumab
AstraZeneca, Daiichi Sankyo
Breast Cancer
09/26
04/29
CompARE, NCT04116047 / 2014-003389-26: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Active, not recruiting
3
785
Europe
Cisplatin, CDDP, Platinol, Durvalumab, MEDI-4736, Imfinzi, Radiotherapy
University of Birmingham, AstraZeneca, Cancer Trials Ireland
Oropharyngeal Cancer
12/26
12/30
BGB-A317-A1217-301, NCT04866017 / 2020-004656-14: A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Calendar Jan 2026 - Dec 2027: Submission for adjuvant/neoadjuvant NSCLC
Terminated
3
63
US, RoW
Tislelizumab, BGB-A317, Durvalumab, Ociperlimab, BGB-A1217
BeiGene, BeiGene, Ltd.
Non Small Cell Lung Cancer
10/23
10/23
AVANZAR, NCT05687266 / 2021-004606-21: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Recruiting
3
1280
Europe, Canada, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, Durvalumab, MEDI4736, Imfinzi, Carboplatin, Pembrolizumab, Cisplatin, Pemetrexed, Paclitaxel
AstraZeneca, AstraZeneca AB
NSCLC
02/27
02/27
PACIFIC-8, NCT05211895 / 2021-004327-32: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Calendar Jan 2024 - Dec 2024: Data from PACIFIC-8 trial for NSCLC
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with domvanalimab for stage 3 NSCLC (based on PACIFIC-8 trial)
Checkmark Initiated PACIFIC-8 trial in combination with durvalumab for stage 3 unresectable 2L NSCLC
Mar 2022 - Mar 2022: Initiated PACIFIC-8 trial in combination with durvalumab for stage 3 unresectable 2L NSCLC
Recruiting
3
860
Europe, Canada, Japan, US, RoW
Durvalumab, Domvanalimab, Placebo
AstraZeneca, Arcus Biosciences, Inc.
Non-Small Cell Lung Cancer
06/28
08/30
DEEP_OCEAN, NCT04465968: Efficacy and Safety of CRT, Durvalumab and Surgery for SST

Not yet recruiting
3
84
NA
Cisplatin, S1, concurrent radiotherapy, Durvalumab, Surgery
National Cancer Center Hospital East, AstraZeneca, Japan Agency for Medical Research and Development, Japan Clinical Oncology Group
Superior Sulcus Tumor, Non-small Cell Lung Cancer Stage IIB, Non Small Cell Lung Cancer Stage III
08/27
08/30
TROPION-Breast03, NCT05629585 / 2022-002680-30: A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy

Recruiting
3
1075
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Durvalumab, MEDI4736, Capecitabine, XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord, Pembrolizumab, KEYTRUDA®
AstraZeneca, Daiichi Sankyo, SWOG Clinical Trials Partnerships
Breast Cancer
09/27
03/30
TROPION-Breast04, NCT06112379: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Recruiting
3
1728
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Durvalumab, MEDI4736, Pembrolizumab, KEYTRUDA®, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord, Olaparib, LYNPARZA®
AstraZeneca, Daiichi Sankyo
Breast Cancer
03/28
08/30
KEYVIBE-006, NCT05298423: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/)

Recruiting
3
784
Europe, Japan, US, RoW
pembrolizumab/vibostolimab, MK-7684A, durvalumab, IMFINZI®, cisplatin, PLATINOL-AQ®, pemetrexed, ALIMTA®, etoposide, TOPOSAR®, carboplatin, PARAPLATIN®, paclitaxel, TAXOL®, thoracic radiotherapy
Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
09/28
09/29
NVALT28, NCT04597671: Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC

Recruiting
3
170
Europe
Durvalumab, Imfinzi, low-dose PCI, Prophylactic Cranial Irradiation (PCI)
Association NVALT Studies
Carcinoma, Non-Small-Cell Lung
12/28
12/32
EA5181, NCT04092283: Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Active, not recruiting
3
660
US, RoW
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt
National Cancer Institute (NCI)
Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
12/28
12/28
NCT05170204 / 2021-004149-19: A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
121
Europe, Canada, Japan, US, RoW
Alectinib, Entrectinib, Durvalumab
Hoffmann-La Roche
Non-Small Cell Lung Cancer
06/29
04/35
TRITON, NCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients

Recruiting
3
280
US
Durvalumab, Tremelimumab, Pemetrexed, Background Platinum-based Chemotherapy, Pembrolizumab, Carboplatin, Cisplatin
AstraZeneca
Carcinoma, Non-Small-Cell Lung
08/27
03/31
NRG-LU008, NCT05624996: Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Recruiting
3
474
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Image Guided Radiation Therapy, IGRT, image-guided radiation therapy, Image-Guided Radiotherapy, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
NRG Oncology, National Cancer Institute (NCI)
Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
10/31
10/36
2018-003520-37: Rad-IO

Not yet recruiting
2/3
159
Europe
Durvalumab, Mitomycin C, 5-Fluorouracil, Solution for infusion, Powder for solution for injection, Solution for injection/infusion, Imfinzi, Mitomycin C, 5-Fluorouracil
University of Birmingham, AstraZeneca
Muscle invasive bladder cancer, Bladder cancer, Diseases [C] - Cancer [C04]
 
 
NRG-HN004, NCT03258554: Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Checkmark Presentation of P2/3 data for advanced head and neck cancer at ASTRO 2022
Oct 2022 - Oct 2022: Presentation of P2/3 data for advanced head and neck cancer at ASTRO 2022
Active, not recruiting
2/3
196
Canada, US
Cetuximab, C225, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), Canadian Cancer Trials Group, NRG Oncology
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma of Unknown Primary, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
09/22
09/24
RUGB, NCT06214572: Radiation Therapy in Unresectable Gall Bladder Cancer

Recruiting
2/3
249
RoW
Systemic therapy (Gemcitabine plus Cisplatin), RT, Systemic therapy (Gemcitabine plus oxaliplatin), Systemic therapy (Gemcitabine plus Cisplatin plus Durvalumab), Systemic therapy (Gemcitabine plus cisplatin plus nab-paclitaxel)
Tata Memorial Centre
Gall Bladder Cancer
07/29
07/29
NCT04628767: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Recruiting
2/3
249
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-jmdb, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Tripegfilgrastim, Udenyca, Ziextenzo, Therapeutic Conventional Surgery, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
09/27
09/27
RAINBO, NCT05255653: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

Recruiting
2/3
1615
Europe, Canada
Olaparib, Lynparza, Pelvic external beam radiotherapy, EBRT, Chemotherapy, Cisplatin, Carboplatin, Paclitaxel, Durvalumab, Imfinzi, Medroxyprogesterone Acetate, Progestogen, Megestrol Acetate, Vaginal brachytherapy, Observation
Leiden University Medical Center, Institute Gustave Roussy (sponsor p53abn-RED trial), Leiden University Medical center (sponsor MMRd-GREEN trial), University College London (sponsor NSMP-ORANGE trial), Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial), Dutch Gynaecological Oncology Group, Comprehensive Cancer Centre The Netherlands, Cancer Research UK & UCL Cancer Trials Centre, Dutch Cancer Society, AstraZeneca, National Cancer Institute, France, Canadian Institutes of Health Research (CIHR)
Endometrial Cancer
01/30
01/31
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Recruiting
2/3
660
Europe, US, RoW
Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
AbbVie
Hepatocellular Carcinoma
09/30
09/30

Download Options